###begin article-title 0
Genetic analysis of HLA, NA and HPA typing in type 2 diabetes and ASO
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Summary
###end title 2
###begin p 3
###xml 593 594 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 691 699 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
We examined the genetic status of human leucocyte antigens (HLA), human platelet alloantigens (HPA) and neutrophil-specific antigens (NA) in patients with type 2 diabetes mellitus and diabetic arteriosclerosis obliterans (ASO). To our knowledge, the present study is the first report showing the relationship among three genetic factors in type 2 diabetes mellitus and ASO patients. HLA typing was performed by the polymerase chain reaction (PCR)-restriction fragment length polymorphism method. HPA-typing and NA-typing were by a PCR-sequence-specific primer method. The incidence of HLA-DRB1* 1501 was found to be significant in type 2 diabetes and non-diabetic, particularly ASO-positive patients, compared to control subjects. There were no differences in NA1/NA2 between the control and diabetic or non-diabetic ASO groups. However, the frequency of NA2/NA2 in ASO-positive diabetes and non-diabetic ASO patients was significantly higher than controls. The a/b genotype of HPA-5a/5b was significantly lower in type 2 diabetes and non-diabetic ASO-positive patients than in controls. These findings suggest that genetic studies of HLA, NA and HPA could be useful to understand the pathogenesis of type 2 diabetes and ASO.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 159 180 159 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Schwartz <italic>et al</italic>., 1995</xref>
###xml 182 204 182 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">Williams &amp; Tabas, 1995</xref>
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 322 348 322 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Kauffmann-Zeh <italic>et al</italic>., 2000</xref>
###xml 573 586 573 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Kunicki, 2002</xref>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 668 686 668 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">Rauch <italic>et al</italic>., 2001</xref>
###xml 1228 1238 1228 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Bray, 1999</xref>
###xml 1247 1252 1247 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1240 1259 1240 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Bussel <italic>et al</italic>., 2000</xref>
###xml 1268 1273 1268 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1261 1280 1261 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Reiner <italic>et al</italic>., 2000</xref>
###xml 1593 1598 1593 1598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1575 1605 1575 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">Von dem Borne Kr. <italic>et al</italic>., 1981</xref>
###xml 1607 1641 1607 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">Von dem Borne Kr. &amp; Ouwehand, 1989</xref>
###xml 1653 1658 1653 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1643 1665 1643 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">McFarland <italic>et al</italic>., 1991</xref>
###xml 1675 1680 1675 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1667 1687 1667 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Dreyfus <italic>et al</italic>., 1997</xref>
###xml 1283 1288 <span type="species:ncbi:9606">Human</span>
The underlying pathology of atherosclerosis obliterans (ASO) is basically atherosclerosis, and complete occlusions by fresh or old thrombi are often observed (Schwartz et al., 1995; Williams & Tabas, 1995). Recent evidence indicates that the incidence of thrombotic disease is steadily increasing among Asian populations (Kauffmann-Zeh et al., 2000). Epidemiological studies indicate that thrombotic diseases result from complex interactions between susceptibility factors, chronic environmental influences and established intercurrent disorders such as diabetes mellitus (Kunicki, 2002). The critical role of platelets in the thrombotic process is now well accepted (Rauch et al., 2001). At sites of vascular injury, thrombus formation is initiated by binding platelet glycoprotein (GP) Ib to von Willebrand factor and binding platelet GPIa/IIa to collagen, which leads to platelet activation and aggregation by binding platelet GPIIb/IIIa to fibrinogen and von Willebrand factor (Kunicki, 2000). Several polymorphisms in the genes encoding for platelet GPs have been associated with increased platelet adhesiveness and aggregation, and in some studies, they have been associated with an increased risk of arterial thrombosis (Bray, 1999; Bussel et al., 2000; Reiner et al., 2000). Human platelet alloantigens (HPA) are important for sensitization to platelet GP polymorphisms. In general, HPAs play important roles in the pathogenesis of neonatal alloimmune thrombocytopenia and post-transfusion purpura, as well as in some cases of refractoriness to platelet transfusion (Von dem Borne Kr. et al., 1981; Von dem Borne Kr. & Ouwehand, 1989; McFarland et al., 1991; Dreyfus et al., 1997). However, there are few reports available concerning the relationship between type 2 diabetes and diabetic ASO.
###end p 5
###begin p 6
###xml 96 124 96 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Beekhuizen &amp; van Furth, 1993</xref>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 126 147 126 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Jonasson <italic>et al</italic>., 1986</xref>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 290 311 290 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Jonasson <italic>et al</italic>., 1986</xref>
###xml 384 394 384 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Ross, 1993</xref>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 555 582 555 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Diamantopoulos <italic>et al</italic>., 2002</xref>
###xml 593 598 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 584 605 584 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">Tsuchiya <italic>et al</italic>., 2003</xref>
###xml 728 733 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 715 740 711 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">Dijstelbloem <italic>et al</italic>., 2000</xref>
###xml 748 753 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 742 760 738 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Nieto <italic>et al</italic>., 2000</xref>
###xml 771 776 767 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 762 783 758 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Fujimoto <italic>et al</italic>., 2001</xref>
###xml 881 886 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 874 893 866 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Matsuo <italic>et al</italic>., 2000</xref>
###xml 972 977 <span type="species:ncbi:9606">human</span>
###xml 1147 1155 <span type="species:ncbi:9606">patients</span>
Leucocytes have been suggested to play an important role in the development of atherosclerosis (Beekhuizen & van Furth, 1993; Jonasson et al., 1986). The first step in the process of leucocyte infiltration into the sub-endothelial space is adhesion of circulating cells to the endothelium (Jonasson et al., 1986). Thus, the pathogenesis of atherosclerosis appears to be inflammation (Ross, 1993). A recent study suggests genetic predisposition and chronic inflammation play the leading roles in the early stages and in the development of vascular damage (Diamantopoulos et al., 2002; Tsuchiya et al., 2003). In addition, the Fcgammareceptor polymorphism is related to susceptibility of some immunological diseases (Dijstelbloem et al., 2000; Nieto et al., 2000; Fujimoto et al., 2001), and neutrophil-specific antigens (NA)1 and NA2 are located on the Fcgammareceptor IIIb (Matsuo et al., 2000). On the other hand, studies have long suggested associations between certain human leucocyte antigens (HLA) and many autoimmune diseases. With respect to the genetic aspects of thrombotic diseases such as type 2 diabetes mellitus, the HLA haplotype of patients can possibly be considered a potentially important factor in the aetiology, although its role remains unclear.
###end p 6
###begin p 7
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
This study examined the genetic status of HLA, HPA and NA in patients with type 2 diabetes mellitus and diabetic ASO. To our knowledge, this is the first report detailing relationships among these three genetic factors in type 2 diabetes mellitus and ASO patients.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Subjects
###end title 9
###begin p 10
###xml 162 245 162 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997</xref>
###xml 427 434 427 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 37 40 <span type="species:ncbi:9606">men</span>
###xml 48 53 <span type="species:ncbi:9606">women</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
###xml 298 305 <span type="species:ncbi:9606">patient</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
We studied 104 Japanese patients (67 men and 37 women, aged 39-85 years) with type 2 diabetes mellitus, as defined by the American Diabetes Association Criteria (The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997). Seventeen non-diabetic ASO patients were used for patient control subjects. A brief clinical profile of the 104 diabetic patients and 17 non-diabetic ASO patients is presented in Table 1. One hundred and twenty-nine controls were randomly selected from among healthy unrelated Japanese individuals. Approval was obtained from the Institutional Review Board for these studies, and informed consent was obtained in accord with the Declaration of Helsinki.
###end p 10
###begin title 11
Diagnosis of ASO
###end title 11
###begin p 12
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 63 71 <span type="species:ncbi:9606">Patients</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
All patients were evaluated by the ankle-pressure index (API). Patients with an API > 1.0 were considered not to have ASO. Thirty-three patients with API < 1.0 underwent angiography and plethysmography, and 28 were diagnosed as having ASO (Fontain's class I-III). Of these, 21 patients with ASO underwent bypass procedures for femoral and trifurcation occlusive disease. Seventeen non-diabetic ASO patients were also diagnosed with Fontain's class I-III. Of these, 10 patients with ASO underwent bypass procedures.
###end p 12
###begin title 13
HLA DNA typing by PCR-RFLP
###end title 13
###begin p 14
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 345 361 345 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Ota <italic>et al</italic>., 1992</xref>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Genomic DNAs from 104 diabetic patients, 17 non-diabetic patients and 126 healthy control subjects were isolated by phenol extraction of sodium dodecyl sulphate-lysed and proteinase K-treated cells. DNA was amplified by PCR with Taq DNA polymerase, and HLA typing was performed by the PCR-restriction fragment length polymorphism (RFLP) method (Ota et al., 1992). The reaction mixture was subjected to 30 cycles of denaturation at 96-97 degreesC for 1 min, annealing at 55-62 degreesC for 1 min, and extension at 72 degreesC for 2 min in an automated PCR thermal sequencer (Iwaki Glass, Inc., Tokyo, Japan). After amplification, aliquots of the products were digested with allele-specific restriction endonucleases for 3 h after addition of the appropriate reaction buffer. Samples of the amplified and cleaved DNAs were subjected to electrophoresis on 12% polyacrylamide gel in a minigel apparatus (Mupid-2, Cosmo Bio Co., Ltd, Tokyo, Japan). Cleavage of amplified fragments was detected by staining with ethidium bromide, and genotypes were determined on the basis of the RFLP band patterns thus generated.
###end p 14
###begin p 15
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the diabetic and non-diabetic patients
###end p 15
###begin title 16
NA genotyping by PCR-preferential homoduplex formation assay (PHFA)
###end title 16
###begin p 17
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 75 92 75 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">Oka <italic>et al</italic>. (1994)</xref>
###xml 416 421 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 407 428 395 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Fujiwara <italic>et al</italic>., 1996</xref>
###xml 430 434 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">1999</xref>
We applied PCR-preferential homoduplex formation assay (PHFA) developed by Oka et al. (1994) to DNA typing of neutrophil-specific antigens (NA1, NA2 and SH) located on the neutrophil receptor, FcgammaRIIIb. Gene fragments containing the polymorphic sequences corresponding to NA1, NA2 and SH of FcgammaRIIIb, as well as the homologous fragment of FcgammaRIIIa, were amplified by PCR using specific primers (Fujiwara et al., 1996, 1999). Assay procedure was performed according to the manufacturer's instructions (Wakunaga Pharm. Co., Ltd, Hiroshima, Japan).
###end p 17
###begin title 18
HPA DNA typing by enzyme-linked mini-sequence assay (ELMA)
###end title 18
###begin p 19
Gene fragments that contained polymorphic sequences corresponding to HPA-1, HPA-2, HPA-3, HPA-4, HPA-5 and HPA-6 were specifically amplified by the PCR method. Enzyme-linked mini-sequence assay (ELMA) typing was performed according to the manufacturer's instructions (Smitest HPA Genotype ELMA, Sumitomo Metal Industries, Ltd, Ibaraki, Japan).
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 7 8 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 389 402 387 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">Thomson, 1981</xref>
###xml 572 573 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
The chi2 method with continuity correction and Fisher's exact test were used for HLA data analysis. Relative risk was calculated according to Wolf's method with Holdane's correction. Briefly, it was calculated as (a x d)/(b x c), where a, b, c and d are the number of marker-positive patients, marker-negative patients, marker-positive controls and marker-negative controls, respectively (Thomson, 1981). The frequencies of the FcgammaRIIIb and HPA alleles were estimated by a gene-counting method and tested for deviation from the Hardy-Weinberg equilibrium using the chi2 test.
###end p 21
###begin p 22
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Relative frequencies of HLA-DRB1*1501 in type 2 diabetes and ASO patients. N.S. not significant.
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 351 352 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 642 648 642 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
Table 2 shows the HLA-DRB1 alleles in the control and type 2 diabetes patients. The incidence of HLA-DRB1*1501 was found to be significant in type 2 diabetes and non-diabetic ASO-positive patients compared to controls (control vs. ASO-negative diabetic patients, 11.6% vs. 35.5%, P < 0.05; control vs. ASO-positive diabetic patients, 11.6% vs. 60.7%, P < 0.01; control vs. non-diabetic ASO-positive patients, 11.6% vs. 52.9%, P < 0.05). In addition, the incidence of this allele was found to be significant in ASO patients compared to non-ASO patients, although there was no significant difference between diabetic and non-diabetic patients (Fig. 1). On the other hand, another DRB1 allele did not exhibit significant differences.
###end p 24
###begin p 25
Frequencies of HLA-DRB1 alleles
###end p 25
###begin p 26
DM: diabetes mellitus.
###end p 26
###begin p 27
ASO: arteriosclerosis obliterans.
###end p 27
###begin p 28
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 4.187).
###end p 28
###begin p 29
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.01 (chi2 = 11.745).
###end p 29
###begin p 30
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 5.642).
###end p 30
###begin p 31
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 509 510 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
Table 3 shows NA gene frequency in control and type 2 diabetes patients; there were no differences in NA1/NA2 among the control, type 2 diabetes and non-diabetic ASO groups. However, the frequency of NA2/NA2 in ASO-positive diabetic and non-diabetic ASO patients was significantly higher than in controls (control vs. ASO-negative diabetic patients, 12.4% vs. 23.7%, N.S.; control vs. ASO-positive diabetic patients, 12.4% vs. 39.3%, P < 0.05; control vs. non-diabetic ASO-positive patients, 12.4% vs. 41.2%, P < 0.05).
###end p 31
###begin p 32
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Results of genotyping of FcgammaRIIIB in healthy controls and patients
###end p 32
###begin p 33
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 4.570).
###end p 33
###begin p 34
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 4.892).
###end p 34
###begin p 35
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
Table 4 shows the HPA genotypes of the control and diabetic patients. The a/b genotype of HPA-5a/5b was significantly lower in type 2 diabetes and non-diabetic ASO patients than in controls (Control vs. ASO-negative diabetic patients, 7.0% vs. 1.3%, N.S.; control vs. ASO-positive diabetic patients, 7.0% vs. 0%, P < 0.05; control vs. non-diabetic ASO-positive patients, 7.0% vs. 0%, P < 0.05).
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 475 480 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 469 487 466 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Nimer <italic>et al</italic>., 1994</xref>
###xml 495 500 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 489 507 486 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Nakao <italic>et al</italic>., 1994</xref>
###xml 699 704 696 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 692 711 689 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Nomura <italic>et al</italic>., 1998</xref>
###xml 1274 1284 1271 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">Park, 2004</xref>
###xml 1467 1472 1464 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1460 1480 1457 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">Veneri <italic>et al</italic>. (2005)</xref>
###xml 1515 1534 1512 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Helicobacter pylori</italic>
###xml 1887 1892 1884 1889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1872 1900 1869 1897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Diamantopoulos <italic>et al</italic>. (2002)</xref>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
###xml 940 948 <span type="species:ncbi:9606">patients</span>
###xml 1037 1045 <span type="species:ncbi:9606">patients</span>
###xml 1077 1085 <span type="species:ncbi:9606">patients</span>
###xml 1195 1203 <span type="species:ncbi:9606">patients</span>
###xml 1515 1534 <span type="species:ncbi:210">Helicobacter pylori</span>
###xml 1578 1586 <span type="species:ncbi:9606">patients</span>
###xml 1915 1923 <span type="species:ncbi:9606">patients</span>
Polymorphisms of class II genes within the major histocompatibility complex can now be precisely determined by typing using the PCR-RFLP method. For example, serologically defined HLA-DR antigens can be divided into many alleles reflecting the polymorphism of the amino acid sequence in the allelic hypervariable regions of the beta chain. In addition, it has been reported that aplastic anemia patients with HLA-DR2 are likely to respond to immunosuppressive therapy (Nimer et al., 1994; Nakao et al., 1994). We have reported that the frequency of HLA-DR decreased and that of DRB1*0410 significantly increased in immune thrombocytopenic purpura patients with poor response to prednisolone (Nomura et al., 1998). Thus, the analysis of HLA antigens and alleles appears to offer some guidelines for the treatment of autoimmune diseases. In the present study, HLA DRB1*1501 was found to be more common in diabetic, particularly ASO-positive, patients. In addition, this allele was also found to be more common in non-diabetic ASO-positive patients. Thus, the association between patients and DRB1*1501 is not always related to type 2 diabetes, because this association is detected in non-diabetic patients. Type 1 diabetes was reported to be associated with some HLA alleles (Park, 2004). However, for the type 2 allele, such relationship was not detected. On the other hand, the association between HLA and infection is possible to detect. In the recent study, Veneri et al. (2005) reported the relationship between Helicobacter pylori and HLA in immune thrombocytopenic purpura patients. Our findings suggest the hypothesis that HLA regulates immunoreactive inflammation or infection associated with type 2 diabetes or ASO. Thus, analysis of some HLA alleles may provide the information for predicting ASO or type 2 diabetes, if racial differences are taken into account. Diamantopoulos et al. (2002) evaluated 197 patients with type 2 diabetes, and found a significant association between HLA-A3 and carotid intimal media thickness. In the Japanese population, the frequency of HLA-A3 is extremely low. In addition, most DRB1*1501 are associated with HLA-A2, -A24 or -A26. The discrepancy between our results and Diamontopoulos's is thought to depend on racial differences. However, most autoimmune diseases share pathogenetic mechanisms characterized by association with an HLA class II haplotype. Also, the pathogenesis of diabetic or non-diabetic ASO may be heterogeneous; therefore, analysis of a larger population with diverse genetic backgrounds will be needed.
###end p 37
###begin p 38
Genotype frequencies of the six major HPAs
###end p 38
###begin p 39
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 5.625);
###end p 39
###begin p 40
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 4.492);
###end p 40
###begin p 41
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P < 0.05 (chi2 = 4.314).
###end p 41
###begin p 42
###xml 90 114 86 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Ravetch &amp; Perussia, 1989</xref>
###xml 331 336 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 322 343 314 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Lalezari <italic>et al</italic>., 1960</xref>
###xml 345 349 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">1975</xref>
###xml 361 366 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 351 373 343 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">Yomtovian <italic>et al</italic>., 1984</xref>
###xml 642 647 630 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 635 654 623 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Meisel <italic>et al</italic>., 2001</xref>
###xml 675 680 663 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 665 688 653 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">Kobayashi <italic>et al</italic>. (2000)</xref>
###xml 1103 1108 1087 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1097 1116 1081 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Fijen <italic>et al</italic>. (2000)</xref>
###xml 1315 1320 1295 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1308 1328 1288 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Raknes <italic>et al</italic>. (1998)</xref>
###xml 1699 1704 1663 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1692 1711 1656 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">Salmon <italic>et al</italic>., 1991</xref>
###xml 1720 1725 1684 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1713 1732 1677 1696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Flesch <italic>et al</italic>., 1998</xref>
###xml 796 804 <span type="species:ncbi:9606">patients</span>
###xml 943 951 <span type="species:ncbi:9606">patients</span>
###xml 1361 1369 <span type="species:ncbi:9606">patients</span>
FcgammaRIIIb is a glycosylphosphatidylinositol-anchored protein expressed on neutrophils (Ravetch & Perussia, 1989). NA1 and NA2 located on the neutrophil receptor FcgammaRIIIb are known to be involved in disorders such as neonatal alloimmune neutropenia, autoimmune neutropenia and transfusion-related acute lung injury (Lalezari et al., 1960, 1975; Yomtovian et al., 1984). In addition, polymorphisms influencing the binding affinity between the FcgammaRs and IgG of different subclasses are recently thought to be important for individual susceptibility to infection with gram-negative bacteria contributing to periodontal disease (Meisel et al., 2001). Indeed, Kobayashi et al. (2000) reported the importance of the FcgammaRIIIb-NA2 allele for susceptibility to IgG in Japanese periodontitis patients. In the present study, the frequency of NA2/NA2 was found to be significantly higher in ASO-positive type 2 diabetes and non-diabetic ASO patients than in controls. Our results suggest the importance of the NA2 allele in susceptibility to ASO. Apart from some reports of periodontal disease, Fijen et al. (2000) reported that the FcgammaRIIIb-NA2/NA2 allotype appeared associated with meningococcal disease. However, previous reports have not always noted the importance of the NA2 allele. For example, Raknes et al. (1998) reported that myasthenia gravis patients with the NA1/NA1 genotype had the most severe condition. The function of FcgammaRIIIb is not entirely clear; however, interestingly, FcgammaRIIIb induces actin filament assembly that is a prerequisite for phagocytosis, while cross-linking of the FcgammaRIIIb by immune complexes enhances FcgammaRII mediated phagocytosis (Salmon et al., 1991; Flesch et al., 1998). These functions may be related to the development of atherosclerosis, since the pathogenesis of atherosclerosis includes inflammation. In addition, our results possibly reflect on such a hypothesis.
###end p 42
###begin p 43
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 263 282 263 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Bussel <italic>et al</italic>., 2000</xref>
###xml 284 297 284 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Kunicki, 2000</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">2002</xref>
###xml 330 332 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</sup>
###xml 439 461 439 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Kunicki &amp; Newman, 1992</xref>
###xml 478 480 478 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A1</sup>
###xml 484 485 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 615 620 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 607 627 607 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">Taaning <italic>et al</italic>., 1983</xref>
###xml 639 644 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 629 651 629 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">McFarland <italic>et al</italic>., 1989</xref>
###xml 670 675 670 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 653 682 653 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Mueller-Eckhardt <italic>et al</italic>., 1989</xref>
###xml 1234 1239 1234 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1228 1246 1228 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">Weiss <italic>et al</italic>., 1996</xref>
###xml 1266 1271 1266 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1248 1278 1248 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Gonzalez-Conejero <italic>et al</italic>., 1998</xref>
###xml 1286 1291 1286 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1280 1298 1280 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">Sperr <italic>et al</italic>., 1998</xref>
###xml 1307 1312 1307 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1300 1319 1300 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Carter <italic>et al</italic>., 1999</xref>
###xml 1327 1332 1327 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1321 1339 1321 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Kroll <italic>et al</italic>., 2000</xref>
###xml 1347 1352 1347 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1341 1359 1341 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Baker <italic>et al</italic>., 2001</xref>
###xml 1372 1377 1372 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1361 1384 1361 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Mikkelsson <italic>et al</italic>., 2001</xref>
###xml 1386 1390 1386 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">2002</xref>
###xml 1409 1414 1409 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1392 1421 1392 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Jilma-Stohlawetz <italic>et al</italic>., 2003</xref>
###xml 1574 1577 1574 1577 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">505</sub>
###xml 1650 1651 1646 1647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1681 1682 1677 1678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1698 1699 1694 1695 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1728 1733 1724 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1720 1740 1716 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Santoso <italic>et al</italic>., 1993</xref>
###xml 1767 1772 1763 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1761 1780 1757 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Kroll <italic>et al</italic>. (2000)</xref>
###xml 1927 1928 1923 1924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 2022 2023 2018 2019 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 2437 2442 2433 2438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2419 2449 2415 2445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Gonzalez-Conejero <italic>et al</italic>., 1998</xref>
###xml 1540 1548 <span type="species:ncbi:9606">patients</span>
###xml 1841 1848 <span type="species:ncbi:9606">patient</span>
###xml 2471 2479 <span type="species:ncbi:9606">patients</span>
HPA plays an important role in provoking neonatal alloimmune thrombocytopenic purpura, post-transfusion purpura and refractoriness to platelet transfusion. To date, 10 HPA systems have been described and several additional alloantigen systems have been reported (Bussel et al., 2000; Kunicki, 2000, 2002). In particular, HPA-1 (PlA.), HPA-2 (Ko), HPA-3 (Bak), HPA-4 (Pen) and HPA-5 (Br) have been well established by serological analysis (Kunicki & Newman, 1992). The HPA-1a (PlA1, Zwa) antigen is by far the most common antigen implicated in neonatal alloimmune thrombocytopenia in a Caucasian population (Taaning et al., 1983; McFarland et al., 1989; Mueller-Eckhardt et al., 1989). On the other hand, HPA-4b is responsible for neonatal alloimmune thrombocytopenia in Japanese. This discrepancy in findings would have occurred because the HPA phenotype frequency varies between races. HPA systems also reside on functional platelet receptor proteins. It has been shown by a number of groups that all platelet-specific alloantigens thus far discovered are located on four platelet membrane GPs: GPIIb, GPIIIa, GPIb and GPIa. Thus, it has been reported that polymorphism of HPA is a genetic risk factor for thrombotic diseases (Weiss et al., 1996; Gonzalez-Conejero et al., 1998; Sperr et al., 1998; Carter et al., 1999; Kroll et al., 2000; Baker et al., 2001; Mikkelsson et al., 2001, 2002; Jilma-Stohlawetz et al., 2003). In the present study, the a/b genotype of HPA-5a/5b was significantly lower in type 2 diabetes and non-diabetic ASO patients than in controls. The Lys505Glu amino acid substitution located in the cation-binding domain of alpha2 is responsible for HPA-5b (Bra) and HPA-5a (Brb) epitope formation (Santoso et al., 1993). In a large study, Kroll et al. (2000) found an association between HPA-5 dimorphism in a low-risk patient subgroup with coronary artery disease. In this population, the frequency of Brb homozygous individuals was overrepresented. This finding suggests that the allele 3 (807C; Bra) may increase the risk for thrombotic disease through a quantitative effect on the function that is independent of the genetic effects on expression levels. However, the frequency of phenotype HPA-5b in Japanese is lower than that in Caucasian (8.7 vs. 20.6%). In addition, it has been reported that the probability of HPA-related immunization is strongly associated with HLA class II DR types (Gonzalez-Conejero et al., 1998). A larger number of patients will need to be examined to confirm this possibility.
###end p 43
###begin p 44
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
In conclusion, we performed a genetic analysis of HLA, NA and HPA in Japanese control subjects and type 2 diabetes patients with and without ASO. The incidence of HLA-DRB1*1501 was found to be significant in type 2 diabetes and non-diabetic ASO-positive patients compared with controls, and the frequency of this allele was significant in patients with ASO. The frequency of NA2/NA2 in ASO-positive diabetes and non-diabetic ASO-positive patients was significantly higher than in controls. The a/b genotype of HPA-5a/5b was significantly lower in type 2 diabetes and non-diabetic ASO-positive patients than in controls. These findings suggest that genetic studies of HLA, NA and HPA could be useful to understand the pathogenesis of type 2 diabetes and ASO.
###end p 44
###begin p 45
This study was supported in part by a Research Grant for Advanced Medical Care from the Ministry of Health and Welfare of Japan.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke
###end article-title 47
###begin article-title 48
###xml 22 27 <span type="species:ncbi:9606">human</span>
Monocyte adherence to human vascular endothelium
###end article-title 48
###begin article-title 49
Integrin polymorphisms as risk factors for thrombosis
###end article-title 49
###begin article-title 50
Platelets: new understanding of platelet glycoproteins and their role in disease
###end article-title 50
###begin article-title 51
Association of the platelet glycoprotein Iib HPA-3 polymorphism with survival after acute ischemic stroke
###end article-title 51
###begin article-title 52
Association of the HLA antigens with early atheromatosis in subjects with type 2 diabetes mellitus
###end article-title 52
###begin article-title 53
Fcgammareceptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes
###end article-title 53
###begin article-title 54
Frequency of immune thrombocytopenia in newborns: a prospective study
###end article-title 54
###begin article-title 55
The role of Fcgammareceptor polymorphisms and C3 in the immune defence against Neisseria meningitides in complement-deficient individuals
###end article-title 55
###begin article-title 56
NA1/NA2 antisera inhibit FcgammaRI- but not FcgammaRII-mediated phagocytosis
###end article-title 56
###begin article-title 57
Involvement of Fc gammareceptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura
###end article-title 57
###begin article-title 58
###xml 27 32 <span type="species:ncbi:9606">human</span>
Large-scale DNA typing for human platelet alloantigens by PCR-RHFA (preferential homoduplex-formation assay)
###end article-title 58
###begin article-title 59
Determination of granulocyte-specific antigens on neutrophil Fcgammareceptor IIIb by PCR-preferential homoduplex formation assay, and gene frequencies in the Japanese population
###end article-title 59
###begin article-title 60
Polymorphisms of platelet membrane glycoprotein Ibalpha associated with arterial thrombotic disease
###end article-title 60
###begin article-title 61
Glycoprotein Ib polymorphisms influence platelet plug formation under high shear rates
###end article-title 61
###begin article-title 62
###xml 78 83 <span type="species:ncbi:9606">human</span>
Regional accumulation of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque
###end article-title 62
###begin article-title 63
Vascular biology
###end article-title 63
###begin article-title 64
###xml 99 107 <span type="species:ncbi:9606">patients</span>
The Fcgammareceptor genotype as a risk factor for generalized early-onset periodonitis in Japanese patients
###end article-title 64
###begin article-title 65
###xml 61 65 61 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1648</sub>
The impact of the glycoprotein Ia collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction
###end article-title 65
###begin article-title 66
The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease
###end article-title 66
###begin article-title 67
The molecular immunology of platelet proteins
###end article-title 67
###begin article-title 68
Chronic autoimmune neutropenia due to anti-NA2 antibody
###end article-title 68
###begin article-title 69
Neonatal neutropenia due to maternal isoimmunization
###end article-title 69
###begin article-title 70
Variations in genes encoding neutrophil antigens NA1 and NA2
###end article-title 70
###begin article-title 71
Prenatal diagnosis of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes
###end article-title 71
###begin article-title 72
Testing of maternal sera in pregnancies at risk for neonatal alloimmune thrombocytopenia
###end article-title 72
###begin article-title 73
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Polymorphisms of Fcgamma-receptors RIIa, RIIIa, and RIIIb in patients with adult periodontal diseases
###end article-title 73
###begin article-title 74
Platelet glycoprotein IbalphaHPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death
###end article-title 74
###begin article-title 75
###xml 129 132 <span type="species:ncbi:9606">men</span>
Platelet collagen receptor GPIa (807T/HPA-5) haplotype is associated with an increased risk fatal coronary events in middle-aged men
###end article-title 75
###begin article-title 76
348 cases of suspected neonatal alloimmune thrombocytopenia
###end article-title 76
###begin article-title 77
Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia
###end article-title 77
###begin article-title 78
Involvement of Fcgammareceptor IIIA genotypes in susceptibility to rheumatoid arthritis
###end article-title 78
###begin article-title 79
###xml 58 66 <span type="species:ncbi:9606">patients</span>
An increased HLA DR2 frequency is seen in aplastic anemia patients
###end article-title 79
###begin article-title 80
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombo-cytopenic purpura
###end article-title 80
###begin article-title 81
Simple method for detecting single base substitutions and its application to HLA-DPB1 typing
###end article-title 81
###begin article-title 82
HLA DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers
###end article-title 82
###begin article-title 83
Prediction of the risk of type 1 diabetes from polymorphisms in candidate genes
###end article-title 83
###begin article-title 84
FcgammaRIIA and FcgammaRIIIB polymorpjisms in myasthenia gravis
###end article-title 84
###begin article-title 85
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences
###end article-title 85
###begin article-title 86
###xml 47 52 <span type="species:ncbi:9606">human</span>
Alternative membrane forms of FcRIII (CD16) on human natural killer cells and neutrophils: cell type-specific expression of two genes that differ in single nucleotide substitutions
###end article-title 86
###begin article-title 87
###xml 80 85 <span type="species:ncbi:9606">women</span>
Genetic variants of platelet glycoprotein receptors and risk of stroke in young women
###end article-title 87
###begin article-title 88
The pathogenesis of atherosclerosis: a prospective study for the 1990s
###end article-title 88
###begin article-title 89
###xml 52 57 <span type="species:ncbi:9606">human</span>
Fcgammareceptor III induces actin polymerization in human neutrophils and primers phagocytosis mediated by Fcgamma receptor II
###end article-title 89
###begin article-title 90
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human platelet alloantigens Br(a) and Br(b) are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit alpha2)
###end article-title 90
###begin article-title 91
The intima. Soil for atherosclerosis and restenosis
###end article-title 91
###begin article-title 92
Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central europeans
###end article-title 92
###begin article-title 93
HLA antigens and maternal antibodies in alloimmune neonatal thrombocytopenia
###end article-title 93
###begin article-title 94
Report of the expert committee on the diagnosis and classification of diabetes mellitus
###end article-title 94
###begin article-title 95
A review of theoretical aspect of HLA and disease association
###end article-title 95
###begin article-title 96
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Genetic background of Japanese patients with antineutrophil cytoplasmic antibody- associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangitis
###end article-title 96
###begin article-title 97
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 132 151 <span type="species:ncbi:210">Helicobacter pylori</span>
Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment
###end article-title 97
###begin article-title 98
Neonatal alloimmune thrombocytopenia: detection and characterization of the respomsible antibodies by the platelet immunofluorescence test
###end article-title 98
###begin article-title 99
Immunology of platelet disorders
###end article-title 99
###begin article-title 100
A polymorohism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
###end article-title 100
###begin article-title 101
The response-to-retention hypothesis of early atherosclerosis
###end article-title 101
###begin article-title 102
Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody
###end article-title 102

